Description du projet
L’intelligence artificielle pour obtenir un diagnostic rapide des maladies infectieuses
Les maladies infectieuses ne sont pas identifiées de manière fiable en raison d’un manque de capacité de diagnostic. Un nombre croissant d’agents infectieux ne sont pas facilement ni efficacement identifiés sans recourir à des tests de laboratoire. En conséquence, les médecins prennent en compte les symptômes et ont tendance à prescrire des antibiotiques. Cependant, une telle méthode ne détecte pas si la cause de la maladie repose sur des bactéries ou des virus, ce qui conduit à une prescription inappropriée des médicaments. Le projet EDAS HEALTHCARE, financé par l’UE, propose un système de diagnostic des maladies infectieuses basé sur les données, fruit de cinq années de recherche. Cette technologie avancée est basée sur une combinaison d’algorithmes de mégadonnées et d’apprentissage automatique, et permet le diagnostic des agents pathogènes en quelques secondes et à un coût inférieur à celui des tests en laboratoire.
Objectif
Today, reliable diagnosis of infectious diseases is not available at the Point-Of-Care, when most needed, resulting in Antimicrobial Resistance, High Treatment Costs and Patients’ Dissatisfaction. A growing number of infectious agents – such as pneumonia, tuberculosis, and salmonellosis – with every day are becoming harder to identify and treat correctly without laboratory tests, is the main cause for a massive scale of misuse and overuse of antibiotics. Approximately 30% to 50% of antibiotic use in humans is inappropriate or even unnecessary. Due to lack of diagnosis available (Time-consuming, cost, absence of infrastructure) physicians commonly prescribe antibiotics based on symptoms. However, this approach does not allow to distinguish if the disease is caused by bacteria or viruses on which drug will work and which won't. At EDAS HEALTHCARE, patent approved technology, resulting 5 years of research, developed a data-driven infectious disease diagnosis system that enables the identification of pathogens in real-time. The use of epidemiology and location-based diagnosis combined with big-data & machine learning algorithms results in over 85% accuracy (a case study results). At a fraction of the cost of laboratory tests EDAS Healthcare can provide decision support system to all physicians at any primary care service upon the first patient encounter with the ER or GP or Telemedicine, and help instantly predict the causative agent of infectious diseases (9 different viruses and 5 different bacteria to date). Targeting the infectious disease diagnostic market worth €6Bn p.a. we offer a solution for hospitals ER, Telemedicine, Homecare, and surveillance agencies. Some of them already confirmed their interest in using our service. Within the Phase 1 project we aim at preparing plans for a wide-scale clinical trials, revise our IPR protection strategy and refine our current business model.
Champ scientifique
- medical and health scienceshealth sciencespublic healthepidemiology
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
12000 JERUSALEM
Israël
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.